SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI
CCSI 28.71-2.4%Nov 4 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Quad Sevens who wrote (2975)6/12/1998 7:12:00 AM
From: STLMD  Read Replies (3) of 5736
 
Wade, please be careful in confusing charges with reimbursement. A hospital lab may charge 22-36 dols. for a test but with respect to reimbursement, this varies from Medicare paying $6-7 and private insurers $8-14. So in evaluating the price an institution will pay for the disposable one must take reimbursement into account.

Let's say the lab tech's time is eliminated from the equation, we still have some time from the nurse doing the testing, so I assume the time factor is a wash. The cost for the machine to do the run in the lab is estimated at about $2-5 depending upon the frequency of testing and equipment.

I am skeptical of Dr. Maisels statements in defense of the company since he has been a lifetime proponent of much less aggressive bilirubin monitoring since the incidence of kernicterus is quite low to nonexistent(research his past pre-CCSI affiliation articles). In addition, as I posted in previous notes the FDA 510k states that out of over 1300 babies in the study only 170 underwent the Colormate III because the others did not have jaundice. It's right there in print. How can we now assume that the market will be 90% of all infants as Dr. Maisels predicts?

This is a great device. I anticipate it will replace a lot of the current marketplace. I admit I do not know what role parental demand will play in this market but to base future earnings revenue on statements such as all parents will demand to have their infants tested, etc. is investor's folly.

Finally, the Dreyfus affair is the catalyst to this entire short position portrayed by Asensio. He knew about it, knew that Dreyfus would be dumping their shares, knew that disclosure by the fund manager was not done, and knows just enough about the bili market to weave a carefully woven trail of mistruths.

I ask all longs to do their homework based on probably at the maximum 5 million tests per year(15 mil x 33% penetration) although I feel the 15 million may be high. What usually holds up distribution arrangements? Lawyers and Money, right? I for one believe the money is the key here and the major bone of contention between the company's expectations and the reality of the marketing world as seen by the distributor. Good luck, wise and thorough investing to all longs. Stephen
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News